Strategic partnerships Strata Oncology collaborates with major healthcare systems to route cancer biopsies to its high-throughput CLIA lab for rapid genomic sequencing and patient-specific therapy or trial matching, presenting a scalable channel for enterprise account acquisition and expanded payer conversations.

Precision care expansion The company’s focus on integrating molecular profiling with decision support and clinical trial access indicates clear opportunities to upsell to systems seeking to deepen precision oncology programs, shorten time-to-treatment, and improve patient outcomes.

Clinical trial linkage Strata PATH-like trial partnerships with industry players (e.g., Gilead collaboration) showcase a revenue and value proposition around matching eligible patients to targeted therapies, suggesting joint marketing and co-sell opportunities with biopharma and contract research organizations.

Rapid results capability Delivering sequencing results to oncologists within days enables faster decision-making; sales upshots include selling to hospital networks and cancer centers seeking operational efficiencies, throughput gains, and improved physician satisfaction.

Recognition and signals Industry recognition such as Diagnostics Innovation Of The Year awards and ongoing fundraising activity signal credibility and growth traction, which can be leveraged in outreach messaging to secure executive sponsorship and shorten sales cycles with larger health systems.